Ser874

Site Information
TNFAGILsQGLrIAP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 31857770
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 )
Disease tissue studied:	lung cancer ( 1 , 2 , 3 , 4 ) , non-small cell lung cancer ( 3 , 5 ) , non-small cell lung adenocarcinoma ( 3 , 4 ) , non-small cell squamous cell lung carcinoma ( 4 ) , small-cell lung cancer ( 1 , 2 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 3 ) , DMS53 (pulmonary) ( 2 ) , DMS79 (pulmonary) ( 1 ) , HCC15 (pulmonary) ( 4 ) , HeLa (cervical) ( 6 ) , LOU-NH91 (squamous) ( 4 ) , lung ( 1 , 2 , 3 , 4 ) , NCI-H128 (pulmonary) ( 1 ) , NCI-H1355 (pulmonary) ( 3 ) , NCI-H1417 (pulmonary) ( 1 ) , NCI-H1703 (squamous) ( 4 ) , NCI-H1792 (pulmonary) ( 3 ) , NCI-H2073 (pulmonary) ( 4 ) , NCI-H209 (pulmonary) ( 1 ) , NCI-H23 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 4 ) , NCI-H3122 (pulmonary) ( 5 ) , NCI-H441 (pulmonary) ( 3 ) , NCI-H446 (pulmonary) ( 2 ) , NCI-H524 (pulmonary) ( 1 ) , NCI-H526 (pulmonary) ( 2 ) , NCI-H69 (pulmonary) ( 2 ) , NCI-H82 (pulmonary) ( 2 )

Upstream Regulation
Treatments:	BI2536 ( 6 )

References
1	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
2	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K (2013) CST Curation Set: 18503; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
6	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info